Vaccination of African penguins (Spheniscus demersus) against high‐pathogenicity avian influenza

Abstract

AbstractBackgroundHigh‐pathogenicity avian influenza (HPAI) has become a conservation threat to wild birds. Therefore, suitable vaccine technology and practical application methods require investigation.MethodsTwenty‐four African penguins (Spheniscus demersus) were vaccinated with either a conventional inactivated clade 2.3.4.4b H5N8 HPAI whole virus or a tobacco leaf‐produced H5 haemagglutinin‐based virus‐like particle (VLP). Six birds received a second dose of the inactivated vaccine. Antibody responses were assessed and compared by employing haemagglutination inhibition tests.ResultsA second dose of inactivated vaccine was required to induce antibody titres above the level required to suppress virus shedding, while a single dose of VLP vaccine produced these levels by day 14, and one bird still had antibodies on day 430.LimitationsBacterial contamination of the VLP vaccine limited the monitoring period and sample size in that treatment group, and it was not possible to perform a challenge study with field virus.ConclusionVLP vaccines offer a more practical option than inactivated whole viruses, especially in logistically challenging situations involving wild birds.